Skip to main navigation

Search for:

Search

Rubius Therapeutics

About Us
Our Science
Our Pipeline
- Pipeline Overview
- Therapeutic Areas
Investors & Media
Careers
Contact

Menu Search

Press Releases

Year

March 3, 2020

Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast

January 30, 2020

Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria

January 13, 2020

Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

January 8, 2020

Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

January 2, 2020

Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 15 of 15

Print Page

RSS Feeds

Share Page

Email Alerts

Contact Us

399 Binney St, Suite 300
Cambridge, MA 02139 617-679-9600

Share

LinkedIn Twitter

Home
About Us
Our Science
Our Pipeline
Investors
Careers
Sitemap
Terms of Use
Privacy Policy

© Rubius Therapeutics, Inc. 2020. All Rights Reserved. RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners.

Facebook
Twitter
LinkedIn